Srikanta Chandra, Avik Das, Tathagata Roy, Preeta Bose, Susanta Paul, Lucky Mukherjee, Arijit Das
Srikanta Chandra1, Avik Das2, Tathagata Roy3, Preeta Bose3, Susanta Paul3, Lucky Mukherjee4, Arijit Das5
1Assistant Professor, Jakir Hossain Institute of Pharmacy, Department of Pharmacology, Raghunathganj, Murshidabad, 742225.
2Assistant Professor, Gupta College of Technological Sciences, Department of Pharmacology, Asansol, West Burdwan, West Bengal, 713301.
3Department of Pharmaceutical Technology, JIS University, Kolkata-700109.
4Assistant Professor, Sister Nivedita University, Kolkata.
5Assistant Professor, Bharat Technology, Uluberia, Howrah.
Volume - 14,
Issue - 3,
Year - 2021
Inflammatory bowel disease is looming large on the modern society which has raised the brows of the medical scientists in both the developed and developing countries. According to American Gastrological Society (AGS) IBD is defined acute or chronic idiopathic ulceroinflammatory condition of the bowel which may or may not have transmural stretch. IBD encompasses two pivotal kinds of pathological condition Ulcerative colitis (UC) and Crohn’s disease (CD). Epidemiologically UC has a greater prevalence in the global prospective. So we decided to zero in on UC in our work ahead. Pivotal contours may be featured as toxic megacolon, pseudopolyps and backwash ileitis. The featured encountered in the clinical course of the disease are multiferrous spanning from rectal bleeding, abdominal pain, weight loss and malasei. Coming to the option available for management they include both non pharmacological approach and pharmacological approach. Under the nonpharmacological approach life style changes like monitored dieting, exercise may plays a pivotal role and psychological intervention also deployed to control the functional aspects of the disease. On the other hand Salfasalazine and Mesalamine are still considered as a corner stone of the therapy as per as pharmacological approach.
Cite this article:
Srikanta Chandra, Avik Das, Tathagata Roy, Preeta Bose, Susanta Paul, Lucky Mukherjee, Arijit Das. Emergent Strategy in Management of Inflammatory Bowel Disease: A Narrowed in on Novel Drugs. Research J. Pharm. and Tech. 2021; 14(3):1811-1814. doi: 10.5958/0974-360X.2021.00321.8
1. H. Konstantinos Katsanos, A. Konstantinos Papadakis. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics; Gut and Liver. Indian Journal of Pharmaceutical Science. 2017; 11(4): 455-463
2. A. Kathleen, Jurenka. S Julie. Inflammatory Bowel Disease Part I: Ulcerative Colitis-Pathophysiology and Conventional and Alternative Treatment Options. Altern Med Rev. 2003; 8(3): 247 -283
3. J Babickova, A. Hyosin. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory disease. World Journal of Gastroenterology .2015;16(2): 452-458
4. Khor Bernard, Gardet Agnes, Xavier. J Amnik. Genetics and pathogenesis of inflammatory bowel disease. International Journal of Pharmaceutical Science .2011: 17(2): 307-317
5. Autenrieth .M Daniel, Baumgart .C Daniel. Toxic Megacolon, Inflammatory Bowel Disease. Journal of Gastroenterology. 2012; 18(3): 212-219
6. Ravikumar. M, Sandhu K. B. Epidemiology of IBD in childhood. Indian Journal of Pediatrics .2006; 73(8) :717-72
7. Campos -Sales .H, Basso. J.P, Alves F.B.V, Fonseca. C. T M, Bonfa G, Nardini V, Cardoso. B.R.C. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research. 2015; 48(2): 96 -107
8. Lee Sun Hyo, Park -Kyung -Soo, Park Dong I1. Novel treatments for inflammatory bowel disease. The Korean Journal of International Medicine. 2018; 33(1):20-27.
9. A. Katheen, Jurenka. S Julie. Inflammatory Bowel Disease Part I: Ulcerative Colitis–Pathophysiology and Conventional and Alternative Treatment Options. Altern Med Rev .2003; 8(3): 247 -283
10. Narula Neeraj, Rubin. T David, Sands E. Bruce. Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. The American Journal of Gastrology Supplements .2016; 3 (2): 38-44
11. Patel MA, Patel PK, Patel MB. Aqueous Extract of Ficus bengalensis Linn. Bark for Inflammatory Bowel Disease. Journal of Young Pharmacy. 2010; 2(2): 130-136
12. 12.Skroza Nevena, Proietti Ilaria, Pampena Riccardo, Viola La Giorgio, Bernardini Nicoletta, Nicolucci Francesca, Tolino Ersillia, Zuber Sara, Soccodata Valentina, Potenza Concetta. Correlations between Psoriasis and Inflammatory Bowel Diseases. Biomed Research International. 2013; 5(2): 87-95
13. Kim Youjin, Wu G. Alex, Chimedza–Jaja Asha, Graf L. Brittany, Carrie Waterman, et al. Isothiocyanate –enriched Moringa seed extract alleviates ulcerative colitis symptoms in mice. World Journal of Gastroenterology. 2017: 3(2): 410-418
14. Elmasry Ahlam, Daba –Hesham Mohamed, Karef -A. El Amro. Possible Effects of Moringa oleifera versus Ginger (Zingiber officinalis) on Experimental Colitis in Mice. British Journal of Medicine and Medical Research. 2016: 16(2): 1-19
15. Minaiyan Mohsen, Asghari Ghloamreza, Taheri Diana, Saeidi Mozhgan, Esfahani Nasr Salar. Anti –inflammatory effect of Moringa oleifera Lam. Seeds on acetic acid –induced acute colitis in rats. Avicenna Journal of Phytomedicine. 2014: 4(2): 127-136
16. 16.MENG-Yue Wan, QING –You Zhu, BING Xia, JUN Luo. Treating TNBS –Induced colitis in rats with probiotics. Turkey Journal of Gastroenterology. 2011: 22(5): 486-493
17. 17.Rejaie S AL-Salim, Abuohasish M Hatem, Enazi M Al- Mahar, Assaf H Al-Abdullah, M Parmar Y Mihir, et al. Protective effect of naringenin on acetic acid –induced ulcerative colitis in rats; World Journal of Gastroentroenterology. 2013: 19(34): 5633-5644
18. Somani S J, Badgujar L B, Sutariya B K, Saraf M N. Protective effect of Dillenia indica L. acetic acid induced colitis in mice. Indian Journal of Experimental Biology. 2014: 52 (4): 876-881